HIV-Associated Lymphoma in a TB-Negative Patient with CD4 Count >200

Why Lymphoma Still Occurs Despite CD4 >200

Fig. 6.43 - Robbins, Cotran & Kumar Pathologic Basis of Disease

• Even with effective ART and normal/near-normal CD4 counts, HIV drives profound germinal center B-cell hyperplasia early in infection
• In germinal centers, B cells undergo somatic hypermutation and class switching - both processes involve AID-dependent DNA breaks, which are error-prone and can lead to oncogene translocations (MYC for Burkitt, BCL6 for DLBCL)
• Most lymphomas arising in patients with preserved CD4 counts are NOT associated with EBV or HHV-8 - they arise through this translocation-driven pathway
• This explains why the overall lymphoma rate remains elevated in HIV-infected patients even on ART with normal CD4 counts

• With significant immunosuppression (CD4 <200), cytotoxic T cells lose control of EBV/HHV-8-infected B cells
• These then accumulate further mutations and develop into full-blown EBV+ or HHV-8+ lymphomas
• At CD4 <50: Primary CNS lymphoma (median CD4 ~50/μL) - nearly 100% EBV+
• Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 244; Henry's Clinical Diagnosis and Management by Laboratory Methods, p. 774

Types of HIV-Associated Lymphoma and Their CD4 Relationship

Clinical Presentation (at CD4 >200)

• At least 80% present with extranodal disease
• B symptoms (fever, night sweats, weight loss) in ~80% of cases
• Common extranodal sites: CNS (~1/3 of patients), GI tract (~25%), bone marrow (~20%), liver and lung (~10% each)
• Burkitt lymphoma: most frequent in patients aged 10-19 years; characteristic c-myc translocation
• Immunoblastic lymphoma: more common in older patients (>50 years, incidence >3%)
• Harrison's Principles of Internal Medicine 22E, p. 1656

Why TB Negativity Matters Here

• Lymphadenopathy + constitutional symptoms + TB-negative status
• The differential now favors lymphoma, Multicentric Castleman disease (MCD), or other malignancy over TB

Pathology and EBV Association

• ~40% of HIV-related lymphomas overall are EBV-associated
• At higher CD4 counts, EBV-negative lymphomas predominate (driven by germinal center hyperplasia/translocation mechanism)
• EBV-negative Burkitt lymphoma and DLBCL are the key entities at CD4 >200
• African Burkitt: 97% EBV+; HIV-associated Burkitt: only 50% EBV+ - highlighting the different pathogenic pathway
• Henry's Clinical Diagnosis and Management by Laboratory Methods, p. 774; Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 244

Management Principles

1. ART (antiretroviral therapy) - cornerstone; has substantially reduced lymphoma incidence and improves outcomes in those who develop it
   • Use ART regimens that avoid myelosuppressive antiretrovirals (to reduce synergistic toxicity with chemotherapy)
   • Avoidance of cobicistat or HIV protease inhibitors - risk of drug-drug interactions with chemotherapy
2. Chemotherapy - standard combination chemotherapy (R-CHOP or CHOP-based regimens for DLBCL; DA-EPOCH-R for Burkitt)
   • Rituximab (anti-CD20) added for CD20+ tumors - has significantly improved outcomes
   • At CD4 >200: response rates up to 72%, median survival 33 months, disease-free intervals up to 9 years have been reported
   • Goldman-Cecil Medicine, p. 479; Harrison's 22E, p. 1657
3. CNS prophylaxis - important since ~20% of systemic lymphoma patients have leptomeningeal involvement; lumbar puncture is mandatory in staging
4. Emerging therapies - CAR T-cell therapy is now being explored for HIV-positive lymphoma patients (per Hattenhauer et al., 2023)
5. Supportive care - growth factor support (G-CSF) to allow full-dose chemotherapy

Prognosis

• Patients with higher CD4 counts fare better but not as well as HIV-negative lymphoma patients
• Burkitt lymphoma in particular is considered highly curable with intensive chemotherapy
• Primary CNS lymphoma (typically at CD4 <50) has poor prognosis: 2-year survival only 20-30%
• At CD4 >200 with systemic lymphoma and TB-negative status: better prognosis group overall

Recent Literature (2026)

Cancer Incidence in HIV-Positive Patients (TB-Negative, CD4 >200): Current Data

Global Burden - The Headline Numbers (2025)

• 81,300 new cancer cases per year globally are attributable to HIV infection
• 70% of these cases occur in Africa, where they account for >5% of total cancer burden, and >10% in Eastern and Southern Africa
• In North America and Western/Northern Europe, non-Hodgkin lymphoma (NHL) and anal cancer account for a higher proportion of HIV-attributable cancers than cervical cancer or Kaposi sarcoma
• Outside Africa, HIV-attributable cancers represent only 0.1-0.4% of total cancer burden

Overall Cancer Risk in HIV Patients

• At least 6% of all patients with AIDS develop lymphoma at some point during their illness - a 10- to 20-fold increase over the general population (Harrison's 22E)
• The risk of aggressive B-cell lymphoma is ~100-fold higher in HIV-infected persons vs. uninfected people
• The risk of Hodgkin lymphoma is ~30-fold higher in HIV-infected persons
• Overall, people living with HIV (PLWH) have a ~2x elevated cancer risk compared to the general population even in the ART era

CD4-Stratified Cancer Incidence Data - The Key Numbers

• People with CD4 <200 have a 3.5-fold higher risk of infection-related cancers compared to those with CD4 ≥500 (Nicolau et al., J Acquir Immune Defic Syndr, 2024; cohort 1996-2020)
• The 2025 international multicentre cohort by Han WM, Ryom L, Sabin CA et al. (Clin Infect Dis, 2025) specifically quantified cancer risk by degree of immune recovery in patients with sustained viral suppression on ART for >2 years - confirming that CD4 <350 remains associated with malignancy risk even on suppressive ART

HIV-Associated Lymphoma Specifically - Current Incidence Data (2026)

"HIV-associated lymphoma (HAL) accounts for more than 30% of cancer-related deaths in people living with HIV (PLWH). HAL subtypes exhibit 5 to 10 times higher incidence rates compared to HIV-negative lymphomas."

• DLBCL and Burkitt lymphoma are the dominant subtypes at CD4 >200
• Complete remission rates with modern therapy: 60-70% for DLBCL (R-EPOCH), 50-60% for Burkitt lymphoma (CODOX-M/IVAC)
• Only 10% of HAL patients are currently enrolled in immunotherapy trials - a major gap

Temporal Trend: Impact of ART

Why CD4 >200 Still Carries Significant Lymphoma Risk - The Data Point

Summary Table: Your Patient Profile (HIV+, TB-negative, CD4 >200)

Cancer Probability in HIV Patients - Percentage Breakdown

Level 1 - Cancer Type Distribution Among ALL HIV Patients

Global (IARC, Lancet Global Health, August 2025 - 81,300 HIV-attributable cancer cases globally)

In High-Income Countries (Europe/North America - most relevant clinically)

Key finding: In the modern ART era, more than 60% of cancers in HIV patients are now non-AIDS-defining - meaning lung, liver, anal, HPV-related cancers are overtaking the classic AIDS-defining malignancies. This reflects PLWH living longer.

Level 2 - Lymphoma Subtypes as % of ALL HIV-Associated Lymphomas

Level 3 - Percentage Probabilities Specific to CD4 >200 (Your Patient)

Level 4 - HIV-Associated Lymphoma as a Share of Cancer Deaths in PLWH

HIV-associated lymphoma accounts for >30% of all cancer-related deaths in people living with HIV

Summary Visual: "If your HIV patient has cancer, what is the probability it's lymphoma?"

All cancers in PLWH (modern ART era, high-income country):
├── Non-AIDS-defining cancers: 60.8% (lung, liver, anal, HPV-related)
└── AIDS-defining cancers:     39.2%
        ├── NHL/lymphoma:        ~60% of ADC  →  ~23% of all HIV cancers
        ├── Kaposi sarcoma:      ~25% of ADC  →  ~10% of all HIV cancers
        └── Cervical cancer:     ~15% of ADC  →  ~6% of all HIV cancers

Of HIV-associated lymphomas specifically:
├── DLBCL:              ~50-60%
├── Primary CNS lymphoma: ~20%
├── Burkitt lymphoma:    ~10-20%
├── PEL:                 ~2-4%
└── Plasmablastic:       ~2%

At CD4 >200 specifically:
→ Burkitt lymphoma and EBV-negative DLBCL predominate
→ Primary CNS lymphoma is effectively ruled out
→ HAL = >30% of all cancer deaths in PLWH regardless of CD4

One Key Number to Remember